Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Net Cash Flow (2022 - 2025)

Historic Net Cash Flow for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$3.8 million.

  • TriSalus Life Sciences' Net Cash Flow rose 2676.68% to -$3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year increase of 21404.7%. This contributed to the annual value of -$3.3 million for FY2024, which is 23203.41% down from last year.
  • According to the latest figures from Q3 2025, TriSalus Life Sciences' Net Cash Flow is -$3.8 million, which was up 2676.68% from $13.5 million recorded in Q2 2025.
  • TriSalus Life Sciences' 5-year Net Cash Flow high stood at $17.5 million for Q3 2023, and its period low was -$17.8 million during Q3 2022.
  • Moreover, its 4-year median value for Net Cash Flow was -$2.7 million (2022), whereas its average is -$484266.7.
  • In the last 5 years, TriSalus Life Sciences' Net Cash Flow tumbled by 1578595.22% in 2023 and then skyrocketed by 53698.92% in 2024.
  • Over the past 4 years, TriSalus Life Sciences' Net Cash Flow (Quarter) stood at -$2.7 million in 2022, then tumbled by 255.5% to -$9.5 million in 2023, then surged by 70.93% to -$2.8 million in 2024, then crashed by 37.64% to -$3.8 million in 2025.
  • Its last three reported values are -$3.8 million in Q3 2025, $13.5 million for Q2 2025, and $4.5 million during Q1 2025.